{"type":"trials","record":{"id":42087,"source_id":"clinicaltrials-gov","external_id":"NCT03466177","title":"Multimodal Retinal Imaging in the Detection and Follow-up of Alzheimer's Disease","brief_summary":"Because of a shared ontogenic origin, the retina displays similarities to the brain and spinal cord in terms of anatomy, functionality, response to insult, and immunology. Hence, the retina can be approached as an integral part of the central nervous system. The occurence of ocular manifestations in several neurodegenerative pathologies, such as Alzheimer's disease and Parkinson's disease, accentuates the strong relationship between eye and brain. Particularly retinal changes can present a substrate for cerebral changes in these disorders. Offering a 'window to the brain', the transparent eye enables non-invasive imaging of these changes in retinal structure and vasculature. In this project, the potential of retinal biomarkers for e.g. Alzheimer's will be explored with the aim to overcome some of the hurdles in the current management of these pathologies, mainly the lack of techniques for patient screening and early diagnosis. The aim of this clinical trial is to correlate the retinal biomarkers for Alzheimer's with neuro-imaging, and cognitive function. Integrating the results will yield non-invasive retinal biomarkers for clinical research, screening, and follow-up of disease progression in various neurodegenerative disorders.","overall_status":"Unknown","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Universitaire Ziekenhuizen KU Leuven","enrollment":320,"countries":["Belgium"],"start_date":"2018-03-01","completion_date":"2025-12-31","last_update_date":"2023-10-10","source_url":"https://clinicaltrials.gov/study/NCT03466177","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"RetAD","age_range":"50 Years to 85 Years","comparator":null,"organization":"Universitaire Ziekenhuizen KU Leuven","interventions":["Non-invasive, multimodal retinal imaging"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Retinal biomarkers for AD: specificity — 5 years","Retinal biomarkers for AD: sensitivity — 5 years","Retinal biomarkers for AD: number needed to image — 5 years","Retinal biomarkers for AD: area under the curve (AUC) — 5 years","Retinal biomarkers for AD: receiver operating characteristic (ROC) — 5 years","Retinal biomarkers for AD: quantification of cerebral Aβ load by non-invasive retinal imaging against the cerebral Aβ l…","Retinal biomarkers for AD: disease progression by measuring the change from baseline at 2 years and more — 15 years"],"design_description":null,"source_has_results":false},"controlled_terms":["Alzheimer Disease","Alzheimer Dementia","Mild Cognitive Impairment","Dementia","Glaucoma","Age-Related Macular Degeneration","Diabetic Retinopathy","Non-invasive, multimodal retinal imaging"],"relevance_confidence":70,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct03466177","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2018-03-01 to 2025-12-31","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 85 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.918Z","intervention":["Non-invasive, multimodal retinal imaging"],"participants":320,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Retinal biomarkers for AD: specificity — 5 years","Retinal biomarkers for AD: sensitivity — 5 years","Retinal biomarkers for AD: number needed to image — 5 years","Retinal biomarkers for AD: area under the curve (AUC) — 5 years","Retinal biomarkers for AD: receiver operating characteristic (ROC) — 5 years","Retinal biomarkers for AD: quantification of cerebral Aβ load by non-invasive retinal imaging against the cerebral Aβ l…","Retinal biomarkers for AD: disease progression by measuring the change from baseline at 2 years and more — 15 years"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Title supplies longevity context: aging.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["controlled terminology","title context","study type"],"relevance_score":70,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42087","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}